Table 3.
Upper 95th percentiles with 95% CI (unweighted values) for bronchodilator responses for whole study population, healthy and COPD subgroups
| Variables | Study population | Healthy Subgroup | COPD GS2+ | COPD GS2+ (without asthma) | ||
| All | Men | Women | Men and women | Men and women | Men and women | |
| FEV1-based measures | N1=10 217 | N1=4826 | N1=5391 | N1=3922 | N1=1009 | N1=745 |
| ΔFEV1 (ml) | 314 (306 to 324) | 354 (340 to 368) | 265 (257 to 278) | 291 (279 to 309) | 371 (343 to 402) | 341 (323 to 381) |
| ΔFEV1i (%) | 14.6 (14.1 to 15.3) | 14.0 (13.2 to 14.6) | 15.4 (14.5 to 16.0) | 12.5 (11.9 to 13.2) | 30.9 (27.8 to 33.8) | 27.7 (21.6 to 30.9) |
| ΔFEV1p (%) | 10.6 (10.3 to 10.9) | 10.2 (9.9 to 10.6) | 10.9 (10.5 to 11.3) | 10.1 (9.7 to 10.7) | 13.1 (12.3 to 14.6) | 12.3 (11.6 to 13.5) |
| FVC-based measures | N2=9546 | N2=4560 | N2=4986 | N2=3593 | N2=976 | N2=723 |
| ΔFVC (ml) | 395 (381 to 414) | 454 (419 to 486) | 347 (328 to 374) | 337 (317 to 358) | 635 (591 to 678) | 619 (547 to 668) |
| ΔFVCi (%) | 13.3 (12.7 to 13.9) | 12.6 (11.8 to 13.4) | 14.1 (13.2 to 15.1) | 11.2 (10.5 to 12.2) | 29.4 (26.6 to 31.6) | 26.7 (24.4 to 30.6) |
| ΔFVCp (%) | 10.8 (10.4 to 11.4) | 10.4 (9.7 to 10.8) | 11.6 (10.7 to 12.5) | 9.6 (9.1 to 10.3) | 18.0 (17.0 to 19.7) | 17.3 (15.7 to 18.8) |
ΔFEV1 (ml) and ΔFVC (ml) are absolute change after bronchodilator; ΔFEV1i and ΔFVCi are change as a per cent of initial value; ΔFEV1p and ΔFVCp are change as per cent of predicted value. N1 is number with non-missing FEV1 values and N2 is number with non-missing FVC values.
COPD GS2+ = FEV1/FVC <0.7 and FEV1% predicted<80%; COPD GS2+, without asthma = COPD GS2+ but with no self-reported diagnosis of asthma.
In the COPD subgroups, the CIs for individual sites were large due to small sample size (<50).
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.